Experian Reports Strong Growth in H1

1 Mins read

By Elena Vardon

Experian, the leading credit-reporting agency, has announced its financial results for the first half of the fiscal year, reporting a significant increase in pretax profit and revenue growth across all regions.

Strong Financial Performance

Experian posted a pretax profit of $763 million for the six months ended September 30, compared to $517 million during the same period last year. This represents a remarkable on-year increase. The company’s total revenue also showed positive growth, reaching $3.42 billion, up from $3.25 billion. Experian’s performance aligns with its expectations, as both total revenue and organic revenue growth at constant exchange rates were recorded at 5% for the half-year.

Global Growth

Experiencing growth in every region, Experian demonstrates its strength in both B2B and Consumer Services. The North America business, accounting for two-thirds of total revenue, achieved an organic revenue growth of 4% at constant exchange rates. Meanwhile, the company recorded a 1% growth in the U.K. and Ireland, an 8% growth in EMEA and Asia Pacific, and an impressive 11% growth in Latin America, which contributes 15% of revenue.

Outlook and Dividend Declaration

Experian confirms its commitment to organic revenue growth, targeting a range of 4% to 6% at constant exchange rates while striving for modest margin improvement. Consensus estimates compiled by the company project a growth rate of 5.3% for the period. The company also declared an interim dividend of 18.0 cents per share, indicating a slight increase compared to the previous year’s payout.

These results further solidify Experian’s position as a global leader in credit reporting services and showcase its continued growth and profitability.

Related posts

GitLab Stock Surges on First Ever Adjusted Operating Profit

1 Mins read
GitLab’s stock experienced a significant surge on Tuesday following the announcement of its first ever adjusted operating profit. Despite this positive development,…

Virgin Galactic Faces Stock Decline Amid Founder's Money Decision

2 Mins read
Virgin Galactic stock experienced a sharp decline in early trading on Monday due to founder Richard Branson’s announcement that he won’t be…

EyePoint Pharmaceuticals Announces Positive Results in Phase 2 Trial for Macular Degeneration Treatment

1 Mins read
EyePoint Pharmaceuticals, a Massachusetts-based company, revealed exciting news on Monday regarding the second-phase trial of its investigational treatment for macular degeneration. The…

Leave a Reply

Your email address will not be published. Required fields are marked *

− 1 = 2